Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT01135927
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 456
- Registration Number
- NCT01074268
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
- Conditions
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 403
- Registration Number
- NCT01068652
- Locations
- 🇹🇳
Novo Nordisk Investigational Site, Tunisia, Tunisia
The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
- Conditions
- Interventions
- First Posted Date
- 2010-01-06
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 63
- Registration Number
- NCT01043510
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 222
- Registration Number
- NCT01003184
- Locations
- 🇬🇧
Research Site, Livingston, United Kingdom
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 548
- Registration Number
- NCT00978627
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin
- Conditions
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT00941148
- Locations
- 🇩🇪
ikfe GmbH, Clinic Department, Mainz, RLP, Germany
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 457
- Registration Number
- NCT00909480
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Pathumthani, Thailand
Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues
- Conditions
- Interventions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 417
- Registration Number
- NCT00873639
- Locations
- 🇷🇴
Novo Nordisk Investigational Site, Bucharest, Romania
Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
- Conditions
- Interventions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00873223
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.